Aradigm Corporation Presents Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis at 2009 International Conference of the American Thoracic Society

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (“Aradigm”) today announced it is presenting data from its Phase 2a studies of inhaled liposomal ciprofloxacin in cystic fibrosis (CF) and in non-CF bronchiectasis (BE) patients at the 2009 International Conference of the American Thoracic Society in San Diego, California.